Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human B-cell progenitors and bone marrow microenvironment

D Campana1, E Coustan-Smith, A Manabe

  • 1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Human Cell
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pneumatic tube transport system carriers made from urethane contaminated with environmental pathogens.

The Journal of hospital infection·2025
Same author

Influence of the Crystallization Firing Process on Marginal and Internal Adaptation of Silicate-based Glass-ceramic Inlays Fabricated With a CAD/CAM Chairside System.

Operative dentistry·2023
Same author

DNA methylation of GJA1, BMP2 and BMP4 in a human cementoblast cell line induced by lipopolysaccharide.

International endodontic journal·2020
Same author

Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature.

Leukemia research·2019
Same author

Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.

The pharmacogenomics journal·2017
Same author

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.

Leukemia·2016

Bone marrow stromal cells support B-cell survival, but CD38 ligation induces apoptosis in immature B-cells via PI 3-K signaling. This stroma-supported culture system aids acute lymphoblastic leukemia (ALL) prognostication and drug screening.

Area of Science:

  • Immunology
  • Cell Biology
  • Hematology

Background:

  • Bone marrow stroma supports normal and leukemic B-cell survival.
  • CD38 is a type II transmembrane protein involved in B-cell regulation.
  • Phosphatidylinositol 3-kinase (PI 3-K) is a key intracellular signaling molecule.

Purpose of the Study:

  • To investigate the role of CD38 ligation in immature B-cell apoptosis within a bone marrow stroma-supported culture system.
  • To explore the clinical applications of stroma-supported cultures for acute lymphoblastic leukemia (ALL) prognostication and drug sensitivity testing.

Main Methods:

  • Culturing immature B-cells and leukemic lymphoblasts on bone marrow-derived stromal layers.
  • Stimulating cells via CD38 ligation and assessing cell growth and apoptosis.

Related Experiment Videos

  • Utilizing PI 3-K inhibitors (Wortmannin, LY294002) to evaluate signaling pathways.
  • Comparing the cytotoxic effects of dexamethasone and prednisolone on ALL cells.

    • Main Results:

    • CD38 ligation on immature B-cells in stroma-supported cultures inhibited growth and induced apoptosis.
    • CD38 ligation activated intracellular substrates, including PI 3-K, and this pathway was crucial for growth suppression.
    • Stroma-supported ALL cell growth was a prognostic indicator in children undergoing chemotherapy.
    • 2-chloro-deoxyadenosine and interleukin-4 showed promise in drug sensitivity assays, leading to clinical trials.
    • Dexamethasone demonstrated significantly higher cytotoxicity than prednisolone in ALL cells.

    Conclusions:

    • CD38 signaling, particularly through PI 3-K, plays a critical role in regulating immature B-cell apoptosis.
    • Stroma-supported in vitro culture systems are valuable tools for predicting ALL patient outcomes and identifying effective antileukemic therapies.
    • Dexamethasone may be a more effective therapeutic agent than prednisolone for ALL treatment, guiding dosage selection.